Setmelanotide, a daily injection that fires the brain's fullness receptor directly, cut body-mass index by 16.5 percent over a year in people whose obesity comes from a physically damaged hypothalamus. The placebo group gained 3.3 percent over the same year. The full results of the phase 3 trial, called TRANSCEND, were published July 9 in the New England Journal of Medicine ↗.
That gap, a drop of about a sixth of body weight against a small gain, is the clearest data yet for a condition with almost no approved treatment before this drug.
What acquired hypothalamic obesity is
The hypothalamus is the small region at the base of the brain that reads the body's fullness signals and decides when to stop eating. A tumor there, most often a childhood craniopharyngioma, or the surgery and radiation used to remove it, can wreck that circuitry. The result is relentless hunger and rapid weight gain. Diet, exercise, and ordinary obesity drugs barely touch it. The problem is not willpower or metabolism in the usual sense. The brain simply never registers that the person is full.
This is a rare condition, measured in the low tens of thousands of patients, and it is the indication setmelanotide is already approved for. What was missing until now was the full pivotal dataset behind that approval.
The numbers
TRANSCEND, run by Rhythm Pharmaceuticals, randomly assigned 120 participants two-to-one to setmelanotide or placebo, injected once daily for 52 weeks after a dose-escalation period. Participants ranged from 4 to 66 years old, with a mean age of about 20. The adults started at a mean BMI of 41, well into severe obesity.
The primary endpoint was the average percent change in BMI at one year. Setmelanotide delivered minus 16.5 percent (95 percent confidence interval minus 19.3 to minus 13.8); placebo moved plus 3.3 percent (95 percent confidence interval minus 0.6 to plus 7.2). The difference was highly significant, with a p-value below 0.001. Hunger, scored daily on a 0-to-10 scale, fell 2.73 points on the drug versus 1.45 on placebo. Reported appetite dropped further than placebo could explain (p-value 0.009).
Why it works here
Setmelanotide is a cyclic eight-amino-acid peptide that switches on the melanocortin-4 receptor ↗, the downstream node that the satiety circuit runs through. When a lesion cuts the upstream signal, that receptor stops getting told the body is full. The drug fires the receptor directly, below the break, which is why it can restore a fullness signal the damaged tissue can no longer send. Sold as Imcivree ↗, it was the first precision-medicine obesity therapy. It was approved in 2020 for rare biallelic POMC, PCSK1, and LEPR deficiencies, then reached Bardet-Biedl syndrome and the hypothalamic indication.
The mechanism also explains the side effects. Nearly everyone on the drug reported an adverse event and 28 percent had a serious one, against 90 percent and 8 percent on placebo. The most common were skin hyperpigmentation, nausea, vomiting, and headache. The darkening skin is a mechanistic tell: the melanocortin system that governs appetite also governs pigment, and a drug tuned to hit one branch nudges the other.
The line this draws
Read against Rhythm's other 2026 result, TRANSCEND sharpens into something more useful than a single trial win. In May the company's EMANATE program ↗, which tested the same drug in a much larger population defined by single-copy variants in genes upstream of the receptor, missed its weight-loss endpoint in all four substudies at once. Those patients have partial loss of the signal. The hypothalamic patients, like the biallelic-genetic patients before them, have the circuit broken outright.
So the drug is not a general obesity treatment that happens to work in rare cases. It is a precision tool. It works only where the melanocortin satiety switch is fully off, whether a mutation silenced it or a tumor destroyed the tissue around it. Where the switch is merely dimmed, firing the receptor harder does not help. That is a cleaner statement of who this class is for than either result gives on its own. It is also the part neither the trial paper nor the earnings call framed directly.
On peptidemodel, the MC4R target page ↗ hosts the receptor setmelanotide engages alongside the rest of the melanocortin family. It is the small corner of the corpus where obesity biology is a specific broken switch rather than a whole-body set point.